Results 51 to 60 of about 895 (134)

Drug-induced immune-mediated thrombocytopenia due to bevacizumab-FOLFOX therapy: a case report [PDF]

Kosin Medical Journal, 2023
Drug-induced immune thrombocytopenia (DITP) is a very rare disease, with an estimated annual incidence of 10 cases per million. Oxaliplatin and irinotecan are widely used as chemotherapy for high-risk stage II and III colorectal cancer, and DITP has been
Minna Kim, Jong Hoon Lee, Jong Yoon Lee
doaj   +1 more source

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer

Cancer Medicine, Volume 9, Issue 4, Page 1485-1494, February 2020., 2020
Mismatch repair proficient colorectal cancer has been refractory to single‐agent programmed cell death protein 1 inhibitor therapy. Colon GVAX is an allogeneic, whole‐cell, granulocyte‐macrophage colony‐stimulating factor‐secreting cellular immunotherapy that induces T‐cell immunity against tumor‐associated antigens and has previously been studied in ...
Mark Yarchoan, Chiung‐Yu Huang, Qingfeng Zhu, Anna K. Ferguson, Jennifer N. Durham, Robert A. Anders, Elizabeth D. Thompson, Noah S. Rozich, Dwayne L. Thomas II, Julie M. Nauroth, Christina Rodriguez, Arsen Osipov, Ana De Jesus‐Acosta, Dung T. Le, Adrian G. Murphy, Daniel Laheru, Ross C. Donehower, Elizabeth M. Jaffee, Lei Zheng, Nilofer S. Azad   +19 more
wiley   +1 more source

Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes

Journal of Ophthalmology, Volume 2020, Issue 1, 2020., 2020
Purpose. To assess the safety of biosimilar intravitreal aflibercept (CinnaGen Co., Iran) compared to the reference product (Eylea®; Bayer Schweiz AG, Zurich, Switzerland) in rabbit eyes through functional and histologic studies. Methods. Forty New Zealand albino rabbits were recruited to the study and were divided into four groups to be sacrificed at ...
Alireza Lashay, Hamid Riazi-Esfahani, Hooshang Faghihi, Ahmad Mirshahi, Hassan Khojasteh, Alireza Khodabande, Fahimeh Asadi Amoli, Fariba Ghassemi, Fatemeh Bazvand, Elias Khalili Pour, Nazanin Ebrahimiadib, Ali Torkashvand, Elham Delrish, Miguel Rechichi   +13 more
wiley   +1 more source

Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: A systematic review and Bayesian network analysis

Frontiers in Oncology, 2023
ObjectiveIt remains unclear what the best second-line treatment is for patients with small-cell lung cancer sensitive to previous platinum-based chemotherapy.MethodsWe systematically screened randomized controlled trials from several online databases ...
Hekai Shi, Nuojin Guo, Zeming Zhao, Ligang Liu, Tianyi Ni, Jinye Zhang, Yingjie Lu   +6 more
doaj   +1 more source

Ziv-aflibercept use in metastatic colorectal cancer.

J Adv Pract Oncol, 2013
Rodriguez M.
europepmc   +4 more sources

Intraocular Pharmacokinetics and Safety of Subretinal Injection Compared with Intravitreal Application of Conbercept in Vitrectomized Rabbit Eyes

Journal of Ophthalmology, Volume 2020, Issue 1, 2020., 2020
Purpose. To evaluate the ocular pharmacokinetic properties of subretinal conbercept injection in vitrectomized rabbit eyes and to compare them with those by intravitreal injection. Methods. The following groups of New Zealand white rabbits received conbercept injections (0.5 mg/0.05 ml): a subretinal group (subretinal injection in vitrectomized eyes ...
Teng-teng Yao, Xiao-liang Jin, Yuan Yang, Yi-xiao Wang, Ya-li Zhou, Fang-lin He, Zhao-yang Wang, Hamid Ahmadieh   +7 more
wiley   +1 more source

Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal vasculopathy. [PDF]

BMJ Case Rep, 2015
Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy usually treated using photodynamic therapy (PDT) and antivascular endothelial growth factor agents. However, these cases may sometimes be refractory to both PDT and ranibizumab or bevacizumab, and may have persistent intra-retinal fluid. Recently, studies have reported that aflibercept
Videkar C, Kapoor A, Chhablani J, Narayanan R.   +3 more
europepmc   +4 more sources

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib

The Oncologist, Volume 25, Issue 1, Page e75-e84, January 2020., 2020
Abstract Background Trifluridine and tipiracil (FTD + TPI) and regorafenib (REG) are approved treatments for the treatment of refractory metastatic colorectal cancer (mCRC). This study assesses adherence and duration of therapy with FTD + TPI versus REG and explores the effect of sequencing on adherence. Materials and Methods Adults diagnosed with mCRC
Anuj K. Patel, Victoria Barghout, Mihran A. Yenikomshian, Guillaume Germain, Philippe Jacques, François Laliberté, Mei S. Duh   +6 more
wiley   +1 more source

Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact

Asia-Pacific Journal of Ophthalmology, 2017
During the past decade, drugs that inhibit the actions of vascular endothelial growth factor (VEGF) have become standard-of-care treatment for a variety of chorioretinal vascular conditions. The off-label, intravitreal use of ziv-aflibercept (Zaltrap) has provided clinicians with an additional cost-effective drug.
Sumit Randhir, Singh, Avantika, Dogra, Michael, Stewart, Taraprasad, Das, Jay, Chhablani   +4 more
openaire   +2 more sources

A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas. [PDF]

Oncologist, 2018
Abstract Lessons Learned The combination of the antiangiogenic agent ziv-aflibercept and the heat shock protein 90 inhibitor ganetespib was associated with several serious and unexpected adverse events and was not tolerable on the dosing schedule tested.
Meehan R, Kummar S, Do K, O'Sullivan Coyne G, Juwara L, Zlott J, Rubinstein L, Doroshow JH, Chen AP.   +8 more
europepmc   +4 more sources